{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:51:43Z","timestamp":1790952703700,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lungcan.2024.107858","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T02:51:35Z","timestamp":1718765495000},"page":"107858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-6076","authenticated-orcid":false,"given":"Yohei","family":"Asano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-625X","authenticated-orcid":false,"given":"Norio","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Demura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2024.107858_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2024.107858_b0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1634\/theoncologist.5-6-463","article-title":"Management of bone metastases","volume":"5","author":"Coleman","year":"2000","journal-title":"Oncologist."},{"key":"10.1016\/j.lungcan.2024.107858_b0015","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/ijms17101674","article-title":"Cancer cell colonisation in the bone microenvironment","volume":"17","author":"Kan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lungcan.2024.107858_b0020","doi-asserted-by":"crossref","first-page":"18670","DOI":"10.1038\/srep18670","article-title":"Natural history of non-small-cell lung cancer with bone metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lungcan.2024.107858_b0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of survival in patients with bone metastasis of lung cancer","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.lungcan.2024.107858_b0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cllc.2013.05.002","article-title":"Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies","volume":"14","author":"Bauml","year":"2013","journal-title":"Clin. Lung Cancer."},{"key":"10.1016\/j.lungcan.2024.107858_b0035","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107858_b0040","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2024.107858_b0045","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107858_b0050","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107858_b0055","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"KEYNOTE-024 Investigators, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107858_b0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"OAK Study Group, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2024.107858_b0065","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"KEYNOTE-042 Investigators, Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.lungcan.2024.107858_b0070","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.21873\/anticanres.14933","article-title":"Complete response of bone metastasis in non-small cell lung cancer with pembrolizumab: two case reports","volume":"41","author":"Asano","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.lungcan.2024.107858_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.871675","article-title":"The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer","volume":"12","author":"Asano","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2024.107858_b0080","doi-asserted-by":"crossref","first-page":"12425","DOI":"10.1002\/cam4.5952","article-title":"Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis","volume":"12","author":"Asano","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2024.107858_b0085","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107858_b0090","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107858_b0095","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1158\/1078-0432.CCR-17-0606","article-title":"Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice","volume":"23","author":"Ahern","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2024.107858_b0100","doi-asserted-by":"crossref","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.lungcan.2024.107858_b0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jtho.2017.11.121","article-title":"RANKL signaling sustains primary tumor growth in genetically engineered mouse models of lung adenocarcinoma","volume":"13","author":"Faget","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107858_b0110","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1002\/cncr.33802","article-title":"Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden","volume":"27","author":"Ehrenstein","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2024.107858_b0115","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO.2004.08.181","article-title":"Bone imaging in metastatic breast cancer","volume":"22","author":"Hamaoka","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2024.107858_b0120","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2024.107858_b0125","doi-asserted-by":"crossref","first-page":"e1480301","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.lungcan.2024.107858_b0130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2024.107858_b0135","article-title":"Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2024.107858_b0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0000000000000459","article-title":"Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center","volume":"28","author":"Afzal","year":"2018","journal-title":"Melanoma Res."},{"key":"10.1016\/j.lungcan.2024.107858_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697298","article-title":"Immune checkpoint inhibitors with or without bone-targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio","volume":"12","author":"Bongiovanni","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.lungcan.2024.107858_b0150","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.21037\/jtd-21-150","article-title":"Does denosumab offer survival benefits? -our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors","volume":"13","author":"Cao","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2024.107858_b0155","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.3390\/jcm11236901","article-title":"Combination of bone-modifying agents with immunotarget therapy for hepatocellular carcinoma with bone metastases","volume":"11","author":"Chen","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2024.107858_b0160","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.chest.2021.12.656","article-title":"Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: A systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2022","journal-title":"Chest."},{"key":"10.1016\/j.lungcan.2024.107858_b0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s13063-019-3951-x","article-title":"Pharmacodynamics of pre-operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B\/2, translational trial (POPCORN)","volume":"20","author":"Ahern","year":"2019","journal-title":"Trials"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224003921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T01:36:04Z","timestamp":1727228164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224003921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"alternative-id":["S0169500224003921"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107858","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107858"}}